<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00318760</url>
  </required_header>
  <id_info>
    <org_study_id>999905403</org_study_id>
    <secondary_id>05-DA-N403</secondary_id>
    <nct_id>NCT00318760</nct_id>
  </id_info>
  <brief_title>Effect of Clonidine on Responses to Imagery Scripts</brief_title>
  <official_title>Effect of Clonidine on Responses to Imagery Scripts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      - Research has shown that clonidine, a drug originally prescribed to treat high blood&#xD;
      pressure and some symptoms of opioid withdrawal, can help block stress-induced relapse to&#xD;
      heroin and cocaine seeking in rats. However, it does not seem to block cue-induced relapse in&#xD;
      rats. Researchers are interested in studying whether clonidine shows the same pattern of&#xD;
      effects on stress- and cue-induced cravings for heroin or cocaine in humans.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      - To compare the ability of clonidine to reduce stress- and cue-induced cocaine and heroin&#xD;
      craving in drug abusers.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      - Individuals between 18 and 55 years of age who are current cocaine or heroin users.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  This study will consist of two visits: a screening visit to determine eligibility and an&#xD;
           experimental/script session.&#xD;
&#xD;
        -  Before the script session, participants will provide urine and breath samples for&#xD;
           testing. Participants will complete questionnaires to measure their current drug craving&#xD;
           and days since last use of cocaine or heroin.&#xD;
&#xD;
        -  At the start of the script session, participants will receive a dose of clonidine or&#xD;
           placebo as directed by the study researchers. Three hours after dosing, participants&#xD;
           will be read four scripts (two neutral, one stress-inducing, and one drug-cue-related)&#xD;
           with breaks in between each script. After each script, participants will respond to&#xD;
           questions about levels of stress and craving.&#xD;
&#xD;
        -  Participants will provide saliva samples immediately before and during the script&#xD;
           readings, and will also be measured for skin response to the scripts.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background. Stress and exposure to drug-related cues (environmental stimuli previously&#xD;
      associated with drug availability) are considered factors that increase the risk of relapse&#xD;
      to heroin and/or cocaine use. The two factors may act through different neural mechanisms.&#xD;
      Alpha-2 adrenergic agonists, such as clonidine, have been shown to block stress-induced&#xD;
      relapse, but not cue-induced relapse, to heroin and cocaine self-administration in rodents.&#xD;
      The ability of clonidine to attenuate stress- or cue-induced heroin and cocaine craving in&#xD;
      drug abusers has not been tested. It is important to determine, in humans, whether clonidine&#xD;
      blocks the acute effects of only one putative class of relapse precipitants, or whether its&#xD;
      effects are more general.&#xD;
&#xD;
      Scientific goal. To compare the ability of clonidine to reduce stress-induced and cue-induced&#xD;
      cocaine and heroin craving in drug abusers.&#xD;
&#xD;
      Participant population. A total of up to 160 drug abusers using cocaine, heroin, or both will&#xD;
      be enrolled. Target enrollment will include 40% women and 60% minorities (mostly&#xD;
      African-American).&#xD;
&#xD;
      Experimental design and methods. Participants will be randomized to one of three groups&#xD;
      receiving clonidine 0.1 mg, clonidine 0.2 mg, or placebo orally under double-blind&#xD;
      conditions. The study will consist of a single 5-6 hr experimental session in which there&#xD;
      will be baseline measures, drug administration, and four script-guided imagery sets, each&#xD;
      followed by a period of data collection. Three hours after dosing (when peak plasma clonidine&#xD;
      concentrations are reached), participants will be exposed to four scripts: one&#xD;
      stress-inducing, one describing drug cues, and two with neutral content. The standardized&#xD;
      script-guided imagery procedure has previously been shown to reliably induce negative&#xD;
      affective states (stress scripts) and/or craving (stress and drug-cue scripts) compared to&#xD;
      the neutral scripts and to have internal and external validity (Tiffany and Drobes, 1990;&#xD;
      Maude-Griffin and Tiffany, 1996; Taylor et al., 2000; Sinha et al., 1999, 2000, 2003;&#xD;
      Singleton et al., 2003; Tiffany and Haekeneworth, 1991; Elash et al., 1995; Drobes and&#xD;
      Tiffany, 1997; Taylor et al., 2000; Singleton et al., 2003). Outcome measures will include&#xD;
      subjective ratings of drug craving and mood, autonomic response (galvanic skin response&#xD;
      [GSR]), and endocrine responses (salivary cortisol and salivary ?-amylase, a measure of&#xD;
      endogenous adrenergic activity during stress (Chatterton et al., 1996; Nater et al., 2005;&#xD;
      van Stegeren et al., 2005)).&#xD;
&#xD;
      Benefits to participants and/or society. There are no direct benefits to participants.&#xD;
      However, if clonidine is effective in blocking stress-induced and/or cue-induced craving,&#xD;
      then the results will be used as a basis for designing a treatment trial, and drug abusers&#xD;
      and society may benefit from the eventual use of clonidine or other alpha agonists for&#xD;
      prevention of relapse in cocaine and heroin users. In addition, this research will provide&#xD;
      information on the clinical relevance of a preclinical model of relapse, possibly&#xD;
      strengthening arguments for its use in medication development.&#xD;
&#xD;
      Risks to participants. Participants may experience side effects from clonidine such as&#xD;
      sedation and are expected to experience brief, mild psychological stress and drug craving&#xD;
      from the laboratory script procedures. Prior to leaving the session, participants will be&#xD;
      assessed for the presence of continued drug effects. If participants are experiencing any&#xD;
      stress or craving at the end of the session, they will undergo a 10-minute guided relaxation&#xD;
      session, which will be repeated until feelings of stress or craving dissipate, before being&#xD;
      released from the laboratory. Participants may be kept longer than the planned session&#xD;
      length, up to and including staying overnight on the inpatient ward, because of continued&#xD;
      side effects or elevated stress or craving. If the MRP deems it medically necessary,&#xD;
      participants will be sent to JHBMC emergency department for further evaluation and treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 14, 2005</start_date>
  <completion_date type="Actual">August 7, 2013</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective ratings of drug craving and mood</measure>
    <time_frame>1 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Autonomic response (galvanic skin response [GSR])</measure>
    <time_frame>1 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart rate and blood pressure</measure>
    <time_frame>1 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Endocrine responses (salivary cortisol and salivary alpha-amylase)</measure>
    <time_frame>1 hr</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Cocaine Abuse</condition>
  <condition>Heroin Abuse</condition>
  <arm_group>
    <arm_group_label>ARM 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clonidine</intervention_name>
    <description>0.1 or 0.2 mg oral, one dose</description>
    <arm_group_label>ARM 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral capsule 1 dose</description>
    <arm_group_label>ARM 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
               1. Age between 18 and 55;&#xD;
&#xD;
               2. Evidence of current cocaine and/or heroin use (by self-report) with a minimum&#xD;
                  lifetime drug-use duration of 1 year and a minimum current drug use of once in&#xD;
                  the last 30 days;&#xD;
&#xD;
                  EXCLUSION CRITERIA:&#xD;
&#xD;
               1. Hypersensitivity to clonidine or any component of the formulation&#xD;
&#xD;
               2. Schizophrenia or any other DSM-IV psychotic disorder; history of anxiety&#xD;
                  disorder, panic disorder, bipolar disorder; current Major Depressive Disorder&#xD;
&#xD;
               3. Current physical dependence on opioids, cocaine, alcohol, benzodiazepines or&#xD;
                  other sedative-hypnotic; this is an exclusion criterion because we want to&#xD;
                  evaluate the ability of clonidine to affect stress- and cue-induced drug craving&#xD;
                  independent of its effects on drug withdrawal&#xD;
&#xD;
               4. Cognitive impairment severe enough to preclude informed consent or valid&#xD;
                  responses on questionnaires&#xD;
&#xD;
               5. Pregnancy or breast feeding&#xD;
&#xD;
               6. Severely impaired hepatic function&#xD;
&#xD;
               7. Severely impaired renal function, with CLcr &lt; 10 ml/minute&#xD;
&#xD;
               8. Medical conditions that contraindicate or that could complicate clonidine&#xD;
                  administration:&#xD;
&#xD;
                    1. hypotension (SBP &lt;95 or DBP &lt; 40 mm Hg) over several readings&#xD;
&#xD;
                    2. hypertension(SBP &gt;160 mm Hg, DBP &gt;95 mm Hg) over several readings&#xD;
&#xD;
                    3. orthostatic hypotension over several readings or as a consequence of any&#xD;
                       underlying medical disorder (e.g., autonomic insufficiency)&#xD;
&#xD;
                    4. bradycardia (heart rate &lt; 50 bpm) over several readings&#xD;
&#xD;
                    5. cerebrovascular disease or any history of CVA or transient ischemic attack&#xD;
                       (TIA)&#xD;
&#xD;
                    6. documented coronary disease&#xD;
&#xD;
                    7. serious arrhythmia or conduction defect (e.g., second or third degree heart&#xD;
                       block, atrial fibrillation)&#xD;
&#xD;
                    8. sinus node dysfunction, severe bradycardia or symptomatic bradycardia&#xD;
&#xD;
                    9. congestive heart failure&#xD;
&#xD;
               9. Medications that could interact adversely with clonidine: antipsychotics;&#xD;
                  antihypertensives (e.g., beta blockers); antiepileptics; CNS depressants (e.g.&#xD;
                  barbiturates, benzodiazepines, narcotic analgesics, alcohol, or other sedatives);&#xD;
                  cyclosporine; oral hypoglycemic agents or insulin; levodopa; tricyclic&#xD;
                  antidepressants; herbals such as dong quai, ephedra, yohimbe, ginseng, valerian,&#xD;
                  St. John s wort, kava kava, gotu kola&#xD;
&#xD;
              10. Women who are able to get pregnant and are not abstinent from sexual activity&#xD;
                  must agree to use a medically effective form of contraception while in the study.&#xD;
                  Those include:&#xD;
&#xD;
               1. Hormonal contraceptives (birth control pills, injectable hormones, vaginal ring&#xD;
                  hormones),&#xD;
&#xD;
               2. Surgical sterility (tubal ligation or hysterectomy)&#xD;
&#xD;
               3. IUD&#xD;
&#xD;
               4. Diaphragm with spermicide&#xD;
&#xD;
               5. Condom with spermicide&#xD;
&#xD;
        Women who do not agree to use these medically effective forms of contraception while in the&#xD;
        study will be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenzie Preston, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute on Drug Abuse (NIDA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institute on Drug Abuse</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Abduljawad KA, Langley RW, Bradshaw CM, Szabadi E. Effects of clonidine and diazepam on the acoustic startle response and on its inhibition by 'prepulses' in man. J Psychopharmacol. 1997;11(1):29-34.</citation>
    <PMID>9097890</PMID>
  </reference>
  <reference>
    <citation>Benschop RJ, Jacobs R, Sommer B, Sch√ºrmeyer TH, Raab JR, Schmidt RE, Schedlowski M. Modulation of the immunologic response to acute stress in humans by beta-blockade or benzodiazepines. FASEB J. 1996 Mar;10(4):517-24.</citation>
    <PMID>8647351</PMID>
  </reference>
  <reference>
    <citation>Berger SP, Hall S, Mickalian JD, Reid MS, Crawford CA, Delucchi K, Carr K, Hall S. Haloperidol antagonism of cue-elicited cocaine craving. Lancet. 1996 Feb 24;347(9000):504-8.</citation>
    <PMID>8596268</PMID>
  </reference>
  <verification_date>July 8, 2014</verification_date>
  <study_first_submitted>April 25, 2006</study_first_submitted>
  <study_first_submitted_qc>April 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2006</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <keyword>Drug Cue</keyword>
  <keyword>Relapse</keyword>
  <keyword>Stress</keyword>
  <keyword>Craving</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
    <mesh_term>Heroin Dependence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clonidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

